TAK-580 In Gliomas and Other Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 120
Summary
- Conditions
- Low Grade Glioma
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 1 years and 25 years
- Gender
- Both males and females
Description
This is a Phase I clinical trial. A Phase I clinical trial tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug to use for further studies. "Investigational" means that the drug is being studied. The U.S. Food and Drug Administration (...
This is a Phase I clinical trial. A Phase I clinical trial tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug to use for further studies. "Investigational" means that the drug is being studied. The U.S. Food and Drug Administration (FDA) has not approved TAK-580 as a treatment for any disease. This is the first time that TAK-580 will be given to children. There is limited experience with TAK-580 in humans. The purpose of this study is to test the safety TAK-580 in children and adolescent participants with brain tumors. The investigators want to find out what effects, good and/or bad, it has on participants and the participant's brain tumor, and find the dose of TAK-580 that is tolerated by participants without too many side effects to use in Phase II of the study. Research in the laboratory has shown that TAK-580 may have activity against cancer cells. TAK-580 belongs to a group of drugs called type II BRAF inhibitors. BRAF abnormalities are found in cancer cells. There are no type II BRAF inhibitors approved by the FDA for humans at the time of this study's start. TAK-580 functions by binding the mutant BRAF molecule and causing a conformation change in the molecule thereby blocking the signal that tells the tumor cell to divide.
Tracking Information
- NCT #
- NCT03429803
- Collaborators
- PLGA Fund at Pediatric Brain Tumor Foundation
- Millennium Pharmaceuticals, Inc.
- National Cancer Institute (NCI)
- Pacific Pediatric Neuro-Oncology Consortium
- Team Jack Foundation
- Investigators
- Principal Investigator: Karen D. Wright, MD Dana-Farber Cancer Institute